Simone Parisi
Overview
Explore the profile of Simone Parisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
651
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parisi S, Ditto M, Ghellere F, Panaro S, Piccione F, Borrelli R, et al.
Front Immunol
. 2025 Mar;
16:1470488.
PMID: 40066438
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint pain, swelling, and stiffness, affecting approximately 1% of the adult population. Tocilizumab (TCZ), a monoclonal antibody targeting the IL-6...
2.
Farina A, Medico P, Parisi S, Becciolini A, Visalli E, Molica-Colella A, et al.
Mediterr J Rheumatol
. 2025 Jan;
35(4):639-644.
PMID: 39886290
Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics....
3.
Busso C, Parisi S, Andrighetti M, Ditto M, Massazza G, Fusaro E, et al.
Eur J Phys Rehabil Med
. 2025 Jan;
61(1):109-118.
PMID: 39869127
Background: The Achilles tendon is one of the most frequent sites of tendinopathy in both healthy and pathological subjects. An innovative approach for the quantitative assessment of the Achilles tendon...
4.
Cacciapaglia F, De Angelis R, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, et al.
J Rheumatol
. 2025 Jan;
PMID: 39814435
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU...
5.
Priora M, Becciolini A, Celletti E, Di Penta M, Lo Gullo A, Paroli M, et al.
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768862
The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients...
6.
Favalli E, Grossi F, Batticciotto A, Filippini M, Parisi S, Viapiana O, et al.
Rheumatol Ther
. 2024 Dec;
12(1):25-36.
PMID: 39718763
Current literature regarding cancer risk in rheumatic and musculoskeletal diseases (RMDs) is particularly poor and controversial, even though the incidence of malignancy in some patients with RMDs is considered to...
7.
Rotondo C, Perniola S, Parisi S, Cantatore F, Corrado A
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685761
Since the early 1990s, the introduction of biologic disease-modifying antirheumatic drugs (b-DMARDs) in managing rheumatological diseases has revolutionised the course of inflammatory chronic arthritis, improving the quality of life, slowing...
8.
Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, et al.
Minerva Med
. 2024 Oct;
115(4):430-438.
PMID: 39376099
Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA...
9.
Paroli M, Becciolini A, Lo Gullo A, Parisi S, Bravi E, Andracco R, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999494
The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration...
10.
Parisi S, Andrea B, Chiara D, Lo Gullo A, Maddalena L, Palma S, et al.
Curr Res Pharmacol Drug Discov
. 2024 Feb;
6:100178.
PMID: 38419949
Objectives: The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts...